| 蒋会娟,刘俊才,李文博.XELOX方案和FOLFOX4方案治疗中晚期肝癌的对比分析[J].肿瘤学杂志,2017,23(10):868-871. |
| XELOX方案和FOLFOX4方案治疗中晚期肝癌的对比分析 |
| Comparison of XELOX and FOLFOX4 Regimens for Treatment of Advanced Hepatocelluar Carcinoma |
| 投稿时间：2017-03-19 |
| DOI：10.11735/j.issn.1671-170X.2017.10.B007 |
|
 |
| 中文关键词: 肝细胞肝癌 卡培他滨 奥沙利铂 氟尿嘧啶 亚叶酸钙 |
| 英文关键词:hepatocelluar carcinom Capecitabine Oxaliplatin Fluorouracil Leucovorin |
| 基金项目: |
|
| 摘要点击次数: 1829 |
| 全文下载次数: 489 |
| 中文摘要: |
| 摘 要：［目的］ 对比观察XELOX方案和FOLFOX4方案治疗中晚期肝细胞肝癌(HCC)的疗效和安全性。［方法］ 2013年2月至2017年4月，纳入53例中晚期HCC患者并随机分为两组，A组(n=27)XELOX方案治疗，卡培他滨1000mg/m2，口服，2次/d，d1～d14；奥沙利铂130mg/m2，静脉点滴，d1，21d为1个周期。B组(n=26)FOLFOX4方案治疗，奥沙利铂 85mg/m2，静脉点滴，d1；亚叶酸钙200mg/m2，静滴2h后予氟尿嘧啶400mg/m2静推，后续600mg/m2持续静滴2h，d1、d2，每2周为1个周期。比较两组患者的疗效及不良反应。［结果］ A组客观缓解率为14.8%，疾病控制率为59.2%，1年生存率为44.1%；B组客观缓解率为15.4%，疾病控制率为53.9%，1年生存率为37.7%；两组各项指标差异均无统计学意义（P＞0.05）。A组主要不良反应为骨髓抑制、消化道反应、肝功能损害、神经毒性和手足综合征，B组主要不良反应为骨髓抑制、消化道反应、肝功能损害和神经毒性，XELOX组不良反应评分较FOLFOX4组低（P＜0.05）。［结论］ XELOX方案治疗中晚期HCC疗效和标准方案FOLFOX4相当，总体不良反应较轻，患者生活质量较高，依从性较好，值得进一步研究。 |
| 英文摘要: |
| Abstract：［Objective］ To compare the efficacy and toxicity between XELOX regimen and FOLFOX4 regimen in treatment of patients with advanced hepatocelluar carcinoma(HCC). ［Methods］ Fifty three patients with advanced HCC admitted from February 2013 to April 2017 were randomly divided into two groups，27 cases in XELOX group received Capecitabine 1000mg/m2，p.o，bid，d1～14，Oxaliplatin 130mg/m2，ivgtt，q.d，d1，repeated every 3 weeks for one cycle；while 26 cases in FOLFOX4 group received Oxaliplatin 85mg/m2，ivgtt，d1；LV 200mg/m2，ivgtt 2h，d1 and d2，5-Fu 400mg/m2，iv bolus d1 and d2，5-Fu 600mg/m2 CIV 22h d1 and d2，repeated every 2 weeks for one cycle. The efficacy and toxicity were compared between two groups. ［Results］ The objective response rate，disease control rate and 1 year survival in XELOX and FOLFOX4 groups were 14.8% and 15.4%，59.2% and 53.9%，44.1%；and 37.7%，respectively (all P>0.05) . The main toxicity was myelosuppression，digestive tract reaction，liver function damage，neurotoxicity and hand-foot syndrome in XELOX group；while the main toxicity in FOLFOX4 group was myelosuppression，digestive tract reaction，liver function damage and neurotoxicity，the toxicity score of XELOX group was lower than that of FOLFOX4 group(P<0.05).［Conclusion］ The efficacy of XELOX regimen is similar to the standard regimen of FOLFOX4 in treatment of advanced HCC；however，the overall toxicities of XELOX regimen were mild，and the quality of life and compliance of patients are better than those of FOLFOX4 regimen. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |